Search Results 521-530 of 17116 for monoclonal antibody
Vaccination should be delayed by 90 days for their children who received monoclonal antibody or convalescent plasma or were given the diagnosis of COVID-19 — ...
In late 2024, the FDA also approved the use of a new monoclonal antibody drug that uses a lab-made protein that binds to a specific target on a cancer cell to ...
Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such ...
Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19. Related Articles. Mayo Clinic Q&A: What makes the ...
... Monoclonal Antibody Screening Score. Mayo Clin Proc Innov Qual Outcomes. 2023 Apr; 7 (2):109-121 Epub 2023 Jan 11. View PubMed; Shah SZ, Alvarez FG, Sanghavi ...
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find ...
The purpose of this study is to evaluate the safety and drug/body interactions of ABBV-085, and to determine the recommended future study dose (alone or in ...
Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving ...
An FGF23 monoclonal antibody (burosumab) was recently approved by the U.S. Food and Drug Administration for use in patients in whom surgical tumor resection ...
Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift today can have 5X the impact on AI research and technology. But hurry — the match challenge ends 9/19.